High-dose Glucocorticoid Treatment Vs. Glucocorticoid Replacement in Immune Checkpoint Inhibitor Associated Hypophysitis (CORTICI): an Open, Randomised Controlled Trial

Overview

Journal Ann Med

Publisher Informa Healthcare

Date 2025 Jan 25

PMID 39862267

Authors

Verena Theiler-Schwetz

Christian Trummer

Lisa Schmitt

Angelika Terbuch

Barbara Obermayer-Pietsch

Erika Richtig

Stefan Pilz

Affiliations

Soon will be listed here.

Abstract

Objective: One of the most severe endocrine side effects of immune checkpoint inhibitors (ICI) is hypophysitis leading to adrenal insufficiency. Recovery is rare, although it has been reported after high-dose glucocorticoid treatment. This is the first randomised study to evaluate whether hormonal recovery differs in patients treated with high-dose glucocorticoids versus glucocorticoid replacement therapy.

Design/methods: In this single-centre, open, randomised controlled study, patients with ICI associated hypophysitis were randomised 1:1 to high-dose glucocorticoid treatment (1 mg/kg of prednisolone for two weeks, followed by tapering until week 7 and a switch to hydrocortisone 20 mg total daily dose in week 8) or glucocorticoid replacement therapy (hydrocortisone 20 mg total daily dose) over 8 weeks. The primary outcome was the frequency of hormonal axes recovery.

Results: Between 17th April 2019 and 16th September 2022, 18 out of the 20 randomised patients finished the trial; eight completed high-dose, 10 glucocorticoid replacement. Nine patients presented with hyponatraemia, two had typical changes on MRI, 12 had isolated adrenal insufficiency, and six had an additional hormone deficiency. None of the patients in neither group experienced a recovery in adrenal function. One patient in each group showed amelioration of hypogonadism. There was a significant, unfavourable treatment effect of high-dose treatment on HbA1c (mean treatment effect 5.16, 95% confidence interval 0.31 to 10.02, = 0.039).

Conclusions: High-dose glucocorticoid treatment was not effective in restoring adrenal function and leads to adverse effects on glucose metabolism. We therefore do not recommend its use for the treatment of ICI associated hypophysitis, except for compressive symptoms.

References

Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster C . Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016; 15(4):457-65. DOI: 10.1517/14740338.2016.1140743. View

Min L, Hodi F, Giobbie-Hurder A, Ott P, Luke J, Donahue H . Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res. 2014; 21(4):749-55. PMC: 4334697. DOI: 10.1158/1078-0432.CCR-14-2353. View

Husebye E, Castinetti F, Criseno S, Curigliano G, Decallonne B, Fleseriu M . Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. Eur J Endocrinol. 2022; 187(6):G1-G21. PMC: 9641795. DOI: 10.1530/EJE-22-0689. View

Goodman R, Johnson D, Balko J . Corticosteroids and Cancer Immunotherapy. Clin Cancer Res. 2023; 29(14):2580-2587. PMC: 10349688. DOI: 10.1158/1078-0432.CCR-22-3181. View

Schwetz V, Pieber T, Obermayer-Pietsch B . The endocrine role of the skeleton: background and clinical evidence. Eur J Endocrinol. 2012; 166(6):959-67. DOI: 10.1530/EJE-12-0030. View

Faje A, Reynolds K, Zubiri L, Lawrence D, Cohen J, Sullivan R . Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. Eur J Endocrinol. 2019; 181(3):211-219. DOI: 10.1530/EJE-19-0238. View

Maria Corsello S, Salvatori R, Barnabei A, De Vecchis L, Marchetti P, Torino F . Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not). Cancer Chemother Pharmacol. 2013; 72(2):489-90. DOI: 10.1007/s00280-013-2213-y. View

Barter P, Gotto A, LaRosa J, Maroni J, Szarek M, Grundy S . HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007; 357(13):1301-10. DOI: 10.1056/NEJMoa064278. View

Brignola C, De Simone G, Belloli C, Iannone P, Belluzzi A, Gionchetti P . Steroid treatment in active Crohn's disease: a comparison between two regimens of different duration. Aliment Pharmacol Ther. 1994; 8(4):465-8. DOI: 10.1111/j.1365-2036.1994.tb00316.x. View

10.

Juszczak A, Gupta A, Karavitaki N, Middleton M, Grossman A . Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review. Eur J Endocrinol. 2012; 167(1):1-5. DOI: 10.1530/EJE-12-0167. View

11.

Okamura T, Hayakawa T, Kadowaki T, Kita Y, Okayama A, Ueshima H . The inverse relationship between serum high-density lipoprotein cholesterol level and all-cause mortality in a 9.6-year follow-up study in the Japanese general population. Atherosclerosis. 2005; 184(1):143-50. DOI: 10.1016/j.atherosclerosis.2005.03.042. View

11.

Karimi N, Heshmati A, Yahyavi M, Jafarizadeh M, Mohammadzadeh A . Measurability of D-concurrence. Sci Rep. 2019; 9(1):19415. PMC: 6923386. DOI: 10.1038/s41598-019-54247-2. View

12.

Gordon D, Probstfield J, Garrison R, Neaton J, CASTELLI W, Knoke J . High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989; 79(1):8-15. DOI: 10.1161/01.cir.79.1.8. View

13.

Ryder M, Callahan M, Postow M, Wolchok J, Fagin J . Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer. 2014; 21(2):371-81. PMC: 4573438. DOI: 10.1530/ERC-13-0499. View

14.

Maria Corsello S, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F . Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab. 2013; 98(4):1361-75. DOI: 10.1210/jc.2012-4075. View

15.

Byun D, Wolchok J, Rosenberg L, Girotra M . Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017; 13(4):195-207. PMC: 5629093. DOI: 10.1038/nrendo.2016.205. View

16.

Richter B, Neises G, Clar C . Glucocorticoid withdrawal schemes in chronic medical disorders. A systematic review. Endocrinol Metab Clin North Am. 2002; 31(3):751-78. DOI: 10.1016/s0889-8529(02)00008-7. View

17.

Gordon T, CASTELLI W, Hjortland M, Kannel W, DAWBER T . High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977; 62(5):707-14. DOI: 10.1016/0002-9343(77)90874-9. View

18.

Percik R, Criseno S, Adam S, Young K, Morganstein D . Diagnostic criteria and proposed management of immune-related endocrinopathies following immune checkpoint inhibitor therapy for cancer. Endocr Connect. 2023; 12(5). PMC: 10160541. DOI: 10.1530/EC-22-0513. View

19.

Hayashi R, Tamada D, Murata M, Kitamura T, Mukai K, Maeda N . Glucocorticoid Replacement Affects Serum Adiponectin Levels and HDL-C in Patients With Secondary Adrenal Insufficiency. J Clin Endocrinol Metab. 2019; 104(12):5814-5822. DOI: 10.1210/jc.2019-00420. View